prikaz prve stranice dokumenta Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
  Download
PDF 1.93 MB
Scientific paper - Original scientific paper
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
International Journal of Molecular Sciences, 25 (2024), 7; 3992. https://doi.org/10.3390/ijms25073992
Illini, Oliver; Saalfeld, Felix Carl; Christopoulos, Petros; Duruisseaux, Michaël; Vikström, Anders; Peled, Nir; Demedts, Ingel; Dudnik, Elizabeth; Eisert, Anna; Hashemi, Sayed M. S.; Janzic, Urska; Kian, Waleed; Mohorcic, Katja; Mohammed, Saara; Silvoniemi, Maria; Rothschild, Sacha I.; Schulz, Christian; Wesseler, Claas; Addeo, Alfredo; Armster, Karin; Itchins, Malinda; Ivanović, Marija; Kauffmann-Guerrero, Diego; Koivunen, Jussi; Kuon, Jonas; Pavlakis, Nick; Piet, Berber; Sebastian, Martin; Velthaus-Rusik, Janna-Lisa; Wannesson, Luciano; Wiesweg, Marcel; Wurm, Robert; Albers-Leischner, Corinna; Aust, Daniela E.; Janning, Melanie; Fabikan, Hannah; Herold, Sylvia; Klimova, Anna; Loges, Sonja; Sharapova, Yana; Schütz, Maret; Weinlinger, Christoph; Valipour, Arschang; Overbeck, Tobias Raphael; Griesinger, Frank; Jakopović, Marko; Hochmair, Maximilian J.; Wermke, Martin More authors...

Cite this document

Illini, O., Saalfeld, F. C., Christopoulos, P., Duruisseaux, M., Vikström, A., Peled, N. ... Wermke, M. (2024). Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis. International Journal of Molecular Sciences, 25. (7). doi: 10.3390/ijms25073992

Illini, Oliver, et al. "Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis." International Journal of Molecular Sciences, vol. 25, no. 7, 2024. https://doi.org/10.3390/ijms25073992

Illini, Oliver, Felix Carl Saalfeld, Petros Christopoulos, Michaël Duruisseaux, Anders Vikström, Nir Peled, Ingel Demedts, et al. "Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis." International Journal of Molecular Sciences 25, no. 7 (2024). https://doi.org/10.3390/ijms25073992

Illini, O., et al. (2024) 'Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis', International Journal of Molecular Sciences, 25(7). doi: 10.3390/ijms25073992

Illini O, Saalfeld FC, Christopoulos P, Duruisseaux M, Vikström A, Peled N, and sur.. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis. International Journal of Molecular Sciences [Internet]. 2024 April 03 [cited 2025 March 14];25(7). doi: 10.3390/ijms25073992

O. Illini, et al., "Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis", International Journal of Molecular Sciences, vol. 25, no. 7, April 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:146378. [Accessed: 14 March 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
AuthorOliver Illini
AuthorFelix Carl Saalfeld
AuthorPetros Christopoulos
AuthorMichaël Duruisseaux
AuthorAnders Vikström
AuthorNir Peled
AuthorIngel Demedts
AuthorElizabeth Dudnik
AuthorAnna Eisert
AuthorSayed M. S. Hashemi
AuthorUrska Janzic
AuthorWaleed Kian
AuthorKatja Mohorcic
AuthorSaara Mohammed
AuthorMaria Silvoniemi
AuthorSacha I. Rothschild
AuthorChristian Schulz
AuthorClaas Wesseler
AuthorAlfredo Addeo
AuthorKarin Armster
AuthorMalinda Itchins
AuthorMarija Ivanović
AuthorDiego Kauffmann-Guerrero
AuthorJussi Koivunen
AuthorJonas Kuon
AuthorNick Pavlakis
AuthorBerber Piet
AuthorMartin Sebastian
AuthorJanna-Lisa Velthaus-Rusik
AuthorLuciano Wannesson
AuthorMarcel Wiesweg
AuthorRobert Wurm
AuthorCorinna Albers-Leischner
AuthorDaniela E. Aust
AuthorMelanie Janning
AuthorHannah Fabikan
AuthorSylvia Herold
AuthorAnna Klimova
AuthorSonja Loges
AuthorYana Sharapova
AuthorMaret Schütz
AuthorChristoph Weinlinger
AuthorArschang Valipour
AuthorTobias Raphael Overbeck
AuthorFrank Griesinger
AuthorMarko Jakopović
AuthorMaximilian J. Hochmair
AuthorMartin Wermke
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an international, real-world safety and efficacy analysis on patients with EGFR Ex20-positive NSCLC enrolled in a mobocertinib early access program. We explored the mechanisms of resistance by analyzing postprogression biopsies, as well as cross-resistance to amivantamab. Data from 86 patients with a median age of 67 years and a median of two prior lines of treatment were analyzed. Treatment-related adverse events (TRAEs) occurred in 95% of patients. Grade ≥3 TRAEs were reported in 38% of patients and included diarrhea (22%) and rash (8%). In 17% of patients, therapy was permanently discontinued, and two patients died due to TRAEs. Women were seven times more likely to discontinue treatment than men. In the overall cohort, the objective response rate to mobocertinib was 34% (95% CI, 24–45). The response rate in treatment-naïve patients was 27% (95% CI, 8–58). The median progression-free and overall survival was 5 months (95% CI, 3.5–6.5) and 12 months (95% CI, 6.8–17.2), respectively. The intracranial response rate was limited (13%), and one-third of disease progression cases involved the brain. Mobocertinib also showed antitumor activity following EGFR Ex20-specific therapy and vice versa. Potential mechanisms of resistance to mobocertinib included amplifications in MET, PIK3CA, and NRAS. Mobocertinib demonstrated meaningful efficacy in a real-world setting but was associated with considerable gastrointestinal and cutaneous toxicity.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleInternational Journal of Molecular Sciences
Numberingvol. 25, no. 7, 3992
e-ISSN1422-0067
DOIhttps://doi.org/10.3390/ijms25073992
URN:NBNurn:nbn:hr:105:146378
Publication2024-04-03
Document URLhttps://www.mdpi.com/1422-0067/25/7/3992
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2025-03-06 10:19:36